Results 101 to 110 of about 114,825 (244)

CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure

Haematologica, 2009
Rituximab binds an epitope on the CD20 antigen, encompassed in exon 5 of the MS4A1 gene. We sequenced this region and correlated the presence of mutations with CD20 protein expression and response to R-CHOP in patients with diffuse large B-cell lymphoma:
Nathalie A. Johnson, Stephen Leach, Bruce Woolcock, Ronald J. deLeeuw, Ali Bashashati, Laurie H. Sehn, Joseph M. Connors, Mukesh Chhanabhai, Angela Brooks-Wilson, Randy D. Gascoyne   +9 more
doaj   +1 more source

CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB [PDF]

, 1999
Katja Schmitz, Wolfram Brugger, B. Weiss, E. Kaiserling, Lothar Kanz   +4 more
openalex   +1 more source

Functional Recombinant Extra Membrane Loop of Human CD20, an Alternative of the Full Length CD20 Antigen

Iranian biomedical journal, 1996
Iranian Biomedical Journal (IBJ); ISSN 1028 ...
Mohammad Reza Aghasadeghi, Mohammad Ali Shokrgozar, Majid Golkar, Hossein Khanahmad, Mahdi Behdani, Ali Jahanian-Najafabadi, Mohsen Abolhassani, Aida Feiz Barazandeh, Saeid Bouzari, Mahdi Habibi Anbouhi   +9 more
openaire   +3 more sources

TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells

Frontiers in Immunology, 2011
Plasma cells have a heterogeneous phenotype in humans. While bone marrow plasma cells are CD20-CD138+, tonsil plasma cells are CD20+CD138+/- and peripheral plasmablasts are CD20-CD138-.
Alexandrine eGeffroy-Luseau, Alexandrine eGeffroy-Luseau, David eChiron, David eChiron, Géraldine eDescamps, Géraldine eDescamps, Gaëtan eJégo, Gaëtan eJégo, Martine eAmiot, Martine eAmiot, Catherine ePellat-Deceunynck, Catherine ePellat-Deceunynck   +11 more
doaj   +1 more source

Targeting CD20 takes the backseat in CLL [PDF]

Blood, 2019
In this issue of Blood , Burger and colleagues report results from a randomized phase 2 study combining rituximab and ibrutinib vs ibrutinib alone in high-risk, untreated, and previously treated chronic lymphocytic leukemia (CLL) patients. 1 This well-performed study provides clear guidance to the field of CLL that, unlike chemotherapy, rituximab ...
openaire   +3 more sources

The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival

Journal of Immunology Research, 2016
Background. It is controversial whether lymphocyte infiltration exhibited in biopsy specimens is associated with transplant outcomes. This study focused on the effect of CD20-positive B cell infiltration in biopsy specimens from allografts with acute ...
Yan Jiang, Rending Wang, Huiping Wang, Hongfeng Huang, Wenhan Peng, Wenxian Qiu, Jingyi Zhou, Jianghua Chen   +7 more
doaj   +1 more source

Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma [PDF]

, 2000
Lucie Heinzerling, Margarete Urbanek, Jens Oliver Funk, Stefan Peker, O. Bleck, K. Neuber, G�nter Burg, Peter Von Den Driesch, Reinhard Dummer   +8 more
openalex   +1 more source

Very low doses of rituximab in autoimmune hemolytic anemia—an open-label, phase II pilot trial

Frontiers in Medicine
IntroductionAlthough rituximab is approved for several autoimmune diseases, no formal dose finding studies have been conducted. The amount of CD20+ cells differs significantly between autoimmune diseases and B-cell malignancies.
Miriam M. Moser, Renate Thalhammer, Christian Sillaber, Ulla Derhaschnig, Christa Firbas, Ulrich Jäger, Bernd Jilma, Christian Schoergenhofer   +7 more
doaj   +1 more source

CD20-Positive Peripheral T-Cell Lymphoma: Report of a Case after Nodular Sclerosis Hodgkin's Disease and Review of the Literature [PDF]

, 2000
Renee L. Mohrmann, Daniel A. Arber
openalex   +1 more source

CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia

Journal of Translational Medicine
Background Chimeric antigen receptor natural killer (CAR-NK) cells represent a promising advancement in CAR cell therapy, addressing limitations observed in CAR-T cell therapy.
Na Yang, Caili Zhang, Yingchun Zhang, Yuting Fan, Jing Zhang, Xiaojin Lin, Ting Guo, Yangzuo Gu, Jieheng Wu, Jianmei Gao, Xing Zhao, Zhixu He   +11 more
doaj   +1 more source